IFOSLIEVA 2 g contains Ifosfamide, an alkylating antineoplastic agent (nitrogen mustard derivative), supplied with Mesna. Ifosfamide causes DNA cross-linking, inhibiting DNA replication and leading to cancer cell death. Mesna is co-administered to prevent hemorrhagic cystitis by neutralizing toxic metabolites (acrolein) in the urinary tract.

Ifosfamide (with Mesna) is used in:

1. Soft Tissue Sarcomas

2. Osteosarcoma

3. Ewing’s Sarcoma

4. Testicular Cancer (salvage regimens)

5. Non-Hodgkin’s Lymphoma

6. Germ Cell Tumors

Common side effects:

•  Myelosuppression (neutropenia, thrombocytopenia, anemia)

•  Nausea, vomiting

•  Alopecia

•  Fatigue

Specific toxicities:

•  Hemorrhagic cystitis (risk reduced with Mesna + hydration)

•  Neurotoxicity / encephalopathy (confusion, drowsiness)

•  Nephrotoxicity

Serious side effects:

•  Severe infections

•  Electrolyte imbalance

•  Renal failure (rare)

 Monitor CBC, renal function, electrolytes, urine output, and mental status.

Dosage is individualized based on BSA, regimen, and patient condition.

Common dosing regimens:

•  1.2–2 g/m²/day IV for 3–5 consecutive days

•  Given with adequate IV hydration

•  Mesna dose: usually 60–100% of total ifosfamide dose, divided and timed with infusion

2 g strength is commonly used for high-dose regimens and adult patients.


NOTE: This medicine should be taken only under a doctor’s supervision.